Reports estimate that over 500 CDMOs are currently operating worldwide. However, only a small percentage can serve in a consultative capacity and perform non-core, value-added functions alongside the core functions of development and manufacture, clinical trial supply, and commercial packaging. The provision of non-core support services differentiates the good from the great. As the outsourcing landscape continues to evolve, sponsors should consider the impact of such services when developing their RFPs. By imbuing the RFP process with a wider consideration of the full scope of what the CDMO can offer, biopharma companies can maximize their chances of finding a CDMO partner that can provide seamless solutions and reduce vendor management complexity. Read our latest article, Support Services & the Holistic Approach to the RFP Decision-Making Process: https://lnkd.in/eP8eWq5A #CDMO #OutSourcing #BioPharma #LetsTalkFuture
PCI Pharma Services’ Post
More Relevant Posts
-
Reports estimate that over 500 CDMOs are currently operating worldwide. However, only a small percentage can serve in a consultative capacity and perform non-core, value-added functions alongside the core functions of development and manufacture, clinical trial supply, and commercial packaging. The provision of non-core support services differentiates the good from the great. As the outsourcing landscape continues to evolve, sponsors should consider the impact of such services when developing their RFPs. By imbuing the RFP process with a wider consideration of the full scope of what the CDMO can offer, biopharma companies can maximize their chances of finding a CDMO partner that can provide seamless solutions and reduce vendor management complexity. Read our latest article, Support Services & the Holistic Approach to the RFP Decision Making Process: https://lnkd.in/eP8eWq5A #CDMO #OutSourcing #BioPharma #LetsTalkFuture
To view or add a comment, sign in
-
Are you a commercial leader in the #pharma industry? Have you considered the power of the contract sales outsourcing (CSO) model? Get up to date with #IQVIA CSO experts Kirk Harmon and Javier "Jave" Castillo’s recent Fierce Pharma article. In the article, they debunk common misconceptions and explore the remarkable benefits that the CSO model offers in today’s dynamic healthcare market. Read now. https://bit.ly/4ajHZoC
To view or add a comment, sign in
-
Are you a commercial leader in the #pharma industry? Have you considered the power of the contract sales outsourcing (CSO) model? Get up to date with #IQVIA CSO experts Kirk Harmon and Javier "Jave" Castillo’s recent Fierce Pharma article. In the article, they debunk common misconceptions and explore the remarkable benefits that the CSO model offers in today’s dynamic healthcare market. Read now. https://bit.ly/3Qf1BT7
To view or add a comment, sign in
-
Does your #CRO have a strategy to support the unique needs of small and emerging drug sponsors? This article is based on findings from our 2023 Phase II/III CRO Benchmarking — Small Pharma Market report. Read on to explore preferred provider agreements (PPAs) by sponsor company size and the key CRO selection attributes that our small sponsor (R&D <$100M) respondents look for in a clinical trial provider. https://lnkd.in/eJ-UgvwY Allucent PSI CRO AG Rho Innovaderm Research Inc. Eurofins IQVIA #biopharma #clinicaltrials #drugdevelopment
To view or add a comment, sign in
-
Want to know more about the impact Quotient Sciences has on drug development, read this interview with Thierry.
In this new interview with Thierry Van Nieuwenhove, CEO of Quotient Sciences, we discuss the company's unique factors, growth plans, and our essential role as a trusted #CDMO/#CRO outsourcing partner in helping our customers accelerate and innovate their drug programs each day: https://bit.ly/3RLiZza
To view or add a comment, sign in
-
How important is cultural fit with supply partners like CMOs or CDMOs? Join Stephanie Gaulding, CQA, CPGP and Redica Systems on Thursday, February 29th where she will share her thoughts on the significance of cultural fit in pharma outsourcing partnerships, strategies for identifying and evaluating cultural compatibility, and best practices for fostering effective communication. #outsourcing #supplychainstrategy https://lnkd.in/gd7EB-kQ
Webinar - Cultivating Successful Outsourcing Partnerships: The Power of Cultural Fit - Redica Systems
redica.com
To view or add a comment, sign in
-
View December's CDMO Opportunities and Threats report! https://lnkd.in/eTpgrzVP Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData Plc, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections. #cdmo #contractmanufacturing #report
To view or add a comment, sign in
-
Find out more about the key benefits of outsourcing to a CDMO. From expertise and efficiency, access to technology, and accelerated development and commercialisation, the benefits are numerous. Read the full article below. #CDMOLive #CDMO #Pharmaceuticaldevelopment #contractmanufacturing
Have you registered for CDMO Live? Almac Pharma Services' and Almac Sciences’ Heads of Business Development, Brian Eastwood and Simon Hamilton, share the key benefits of outsourcing. Read the full article here: https://hubs.li/Q02yXZrr0 PharmaSource #CDMO #CDMOLive #lifesciencenetworks #pharmasource #contractmanufacturing Aideen Fox Peder Fode
To view or add a comment, sign in
-
"Streamlining Early-Stage Development: A Key to Faster Clinical Trials" Sharing this insightful article by Srinivasan Shanmugam from Adare Pharma Solutions ✅ A standout point from the article is the emphasis on constructing a clear quality target product profile (QTPP) during early-stage development. ✅ This approach not only aids in achieving positive proof of concept (PoC) results but also ensures scalability, thus minimizing downstream development challenges. ✅ This resonates deeply with the vital role of managing vendors, particularly CDMOs (Contract Development and Manufacturing Organizations), in this phase. ⭐ The article highlights the importance of sponsors preparing for early-stage development in advance. ⭐ In the context of vendor management, this underscores the necessity of selecting CDMOs that are not only technically proficient but also strategically aligned with the project’s goals. ⭐ The right CDMO partnership can provide invaluable guidance through regulatory strategies and early-stage challenges, ultimately expediting the journey to clinical trials. Managing vendor relationships effectively becomes paramount, as it ensures continuous collaboration, flexibility, and innovation throughout the development process. 🔗 Read the full article: https://lnkd.in/eNkN8EUa #PharmaceuticalDevelopment #VendorManagement #ClinicalTrials #AdarePharmaSolutions 🚀🧪🤝
To view or add a comment, sign in
54,385 followers
More from this author
-
Rachel Griffiths & Craig LaMarca discuss the growing demand for speed to clinic and market and the significance of partnering with the right CDMO.
PCI Pharma Services 1d -
Building Robust Supply Chains to Prevent Drug Shortages
PCI Pharma Services 4mo -
Navigating the Complex Landscape of Drug-Device Combination Products
PCI Pharma Services 5mo
Sales Director UK & Ireland
1w👏👏👏👏